Lexaria Announces Exercises of Existing Warrants and Options
Kelowna, British Columbia / TheNewswire / June 19, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces warrant and option transactions.
Lexaria announces it has received US$30,000 from the exercise of 50,000 warrants at the price of US$0.60, previously granted to third parties who are neither officers nor directors of the Company. In addition Lexaria has received US$63,000 from the exercise of 450,000 warrants at the price of US$0.14, previously granted to an officer of the Company. Lexaria has also received US$22,500 from the exercise of 247,500 stock options at the price of US$0.091, previously granted to an officer of the Company.
No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
